Navigation Links
Ampio Pharmaceuticals Reports Full-Year 2011 Financial Results and Milestone Highlights for 2011
Date:2/9/2012

GREENWOOD VILLAGE, Colo., Feb. 9, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced financial results for the year ended December 31, 2011, and offered a summary of the milestones during 2011.

Financial ResultsTotal revenues recognized for the year ended December 31, 2011, were $18,750, reflecting the amortized portion of the $500,000 licensing upfront payment from the Company's agreement with a major Korean pharmaceutical company for South Korean rights to Ampio's Zertane™.  The Company did not report any revenues for the year ended December 31, 2010.  

Total operating expenses for the full-year periods ended December 31, 2011 and 2010, were $11,152,891 and $6,704,405, respectively.  Research and development expenses for the full year 2011 were $6,648,397, compared to $1,972,134 for the full year 2010.  The 237% growth in research and development costs during 2011 primarily reflects the increased focus on the Company's multiple clinical trials and proof-of-concept studies.  Specifically, the Company invested significantly in the Phase 2 Ampion™ in the Knee study and the Phase 2 Optina™ study evaluating the product's ability to prevent diabetic macular edema (DME) and in a $2,000,000 fee paid to obtain a product technology license associated with Zertane™.  

General and administrative expenses for the full-year period of 2011 were $4,504,494, compared to $4,732,271 in the full-year period of 2010.  Other expenses were $7,142,593 in the full-year period of 2011, compared to $1,348,990 in the corresponding 2010 period.  The increase in other expenses primarily reflects the $5,585,422 of non-cash changes in the fair value of Ampi
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
2. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
3. Atlanta-based Med Tech Company CardioMEMS Raises Additional Capital to Advance its CHAMPION Clinical Trial for its Wireless Sensor System for Heart Failure Monitoring
4. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
5. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
6. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
7. Chay Enterprises Inc. Completes Merger With Repurposed Drug Developer Ampio Pharmaceuticals, Inc.
8. Ampio Pharmaceuticals, Inc. Retains Redwood Consultants, LLC to Assist in Shareholder Relations and Strategic Planning
9. Ampio Pharmaceuticals to Acquire DMI Biosciences, Inc.
10. Ampio Pharmaceuticals, Inc. Appoints New Chairman and Chief Financial Officer
11. Higher Education Leaders Receive TCWF Champions of Health Professions Diversity Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, ... Drew Young has joined the company as Senior ... will be responsible for leading the strategic direction of ... Bringing more than 20 years of experience ... pharmaceutical and biotech companies, Mr. Young comes to EMD ...
(Date:9/2/2014)... , Sept. 2, 2014  Boston Scientific Corporation (NYSE: ... announced agreement to purchase the Interventional business of ... Boston Scientific to offer physicians and healthcare systems ... challenging vascular conditions. The addition of ... technologies supports the Boston Scientific strategy to provide ...
(Date:9/2/2014)... Mass. , Sept. 2, 2014  Hologic, Inc. (NASDAQ: ... President and Chief Executive Officer, will present at the Morgan ... , New York on Tuesday, ... Interested parties are invited to listen to the live audio ... website at www.hologic.com/investors-overview . An archive of the presentation ...
Breaking Medicine Technology:EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 2EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 3EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 4Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 2Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 3Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 4Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 5
... Conference: February 13-16, 2012 ,Exposition: February ... Organizers of the Medical Design and Manufacturing (MD&M) West ... be held at the Anaheim Convention Center, February 13-16, ... event in the United States dedicated to medical design ...
... N.C., Jan. 20, 2012  As the pace of ... has become challenging for the biopharma industry to ... messages. Consumers, key opinion leaders, payers ... and biotech companies reach out to with marketing ...
Cached Medicine Technology:MD&M West 2012 to Feature Twenty Collocated Conferences 2Utilizing Marketing Innovations to Engage with Customer Groups that are Key to the Pharmaceutical Industry 2
(Date:9/2/2014)... (HealthDay News) -- Drinking and marijuana may lead to ... study suggests. Researchers analyzed 2007 to 2011 data ... who said they had used alcohol or marijuana at ... was associated with more unsafe driving, damage to relationships ... while under the influence of alcohol, especially among females. ...
(Date:9/2/2014)... apnea, tonsillectomies, hearing loss, head and neck cancers ... Orlando, FL, September 21-24, at the 2014 Annual ... of OtolaryngologyHead and Neck Surgery Foundation (AAO-HNSF), the ... and neck physicians in the world. , Abstracts ... today, and are available online at http://oto.sagepub.com/content/151/1_suppl ...
(Date:9/2/2014)... Last year, SIGVARIS took graduated ... of a luxurious line of graduated compression socks with natural ... COTTON Socks are joining the SIGVARIS MEDICAL collection for those ... comfort of natural cotton fibers. , “When people step ... find socks as soft as the finest cashmere,” says Clay ...
(Date:9/2/2014)... 02, 2014 The exclusive ClinicCRM patient ... designed to help doctors manage foreign patient flow, enable ... conversion rates and clink revenue. Since its launch in ... in sales revenue and a 70 percent increase in ... their own healthcare practices. , With its ease of ...
(Date:9/2/2014)... of Experimental Biology and Medicine that ... biology and medicine of microphysiological systems" and describes ... Systems Program directed by the National Center for ... of Health (NIH) and funded in part by ... Projects Agency (DARPA) and the Food and Drug ...
Breaking Medicine News(10 mins):Health News:Booze, Pot Bad for Teens in Different Ways, Study Suggests 2Health News:SIGVARIS’ Luxury Line of Compression Socks, SEA ISLAND COTTON, Now Available in Stronger Compression Level 2Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 2Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 3Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 4Health News:Microphysiological systems will revolutionize experimental biology and medicine 2Health News:Microphysiological systems will revolutionize experimental biology and medicine 3
... , , , ... Sustained reduction of mitral regurgitation following mitral valve repair ... (DMR) or functional mitral regurgitation (FMR) led to heart function ... initial registry cohort of the EVEREST (Endovascular Valve Edge-to-Edge REpair ...
... , , , , ... over 2,000 motorcycle riders and enthusiasts will gather at Wisconsin Harley-Davidson ... "Ridin, to a Cure" fund raiser for breast cancer research in ... raise in excess of $300,000 over the weekend. The ride has ...
... , , One of Nation,s Best ... The health care network operated by the Department of Veterans Affairs (VA) has ... by the American Association of Retired Persons (AARP). , , "Quality ... Affairs Eric K. Shinseki. "VA is proud to be recognized as a top ...
... CHELMSFORD, Mass., Sept. 22 Magellan Biosciences, Inc. (Magellan), ... Life Sciences Tools (LST) business to Sunnyvale, California-based Dionex, Inc. ... ESA,s HPLC-related products, HPLC clinical assays, the ESA Laboratories services ... Financial terms of the transaction were not disclosed. , ...
... VA Physical therapist-directed exercise counseling combined with ... and exercise capacity in people with type 2 ... exercise, according to a randomized clinical trial published ... , the scientific journal of the American Physical ...
... Mo. About 2 million Americans currently use cocaine ... to making it one of the most dangerous and ... cause severe biological and behavioral problems, is very difficult ... and Sandeep Pendyam, doctoral students in the Department of ...
Cached Medicine News:Health News:MitraClip(R) Therapy Data Demonstrate Significant Left Ventricular Reverse Remodeling in Patients With Sustained Reduction of Mitral Regurgitation 2Health News:MitraClip(R) Therapy Data Demonstrate Significant Left Ventricular Reverse Remodeling in Patients With Sustained Reduction of Mitral Regurgitation 3Health News:We Need Your Support - 'Ridin' to a Cure' Sept. 25 and 26 2Health News:VA's Health System Top Employer for AARP 2Health News:Magellan Biosciences Sells its Life Sciences Tools Business to Dionex 2Health News:Magellan Biosciences Sells its Life Sciences Tools Business to Dionex 3Health News:People with type 2 diabetes improved muscular strength 2Health News:Computer model shows changes in brain mechanisms for cocaine addicts 2
Neomycin and Polymyxin B Sulfates and Hydrocortisone otic suspension, USP is a sterile antibacterial and anti-inflammatory suspension for otic use....
Prednisolone Acetate ophthalmic suspension USP, 1% is an adrenocortical steroid product prepared as a sterile ophthalmic suspension....
... A sophisticated research tool that allows ... area which is being stimulated. Besides it ... the examiner to switch between the pupil ... computer screen. This system is especially suited ...
The only air-based esthesiometer with a database of normal sensation on the cornea. May have application to the measurement of normal-tension glaucoma....
Medicine Products: